viimane versioon :
19/11/2024
immunosupressant   Mycophenolate mofetil  
Süsteravim
suukaudne lahus
Stabiilsus lahustes Stabiilsust mõjutavad tegurid stabiilsust mõjutavad faktorid Sobimatus Manustamis viis Viited pdf
   keemiline struktuur  

Kaubanduslikud nimed erinevates maades   Kaubanduslikud nimed erinevates maades     

Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist

Cellcept Ameerika ühendriigid, Austraalia, Austria, Hispaania, Holland, Iirimaa, Itaalia, Jaapan, Kanada, Kolumbia, Kreeka, Luksemburg, Mehhiko, Norra, Poola, Portugal, Prantsusmaa, Rootsi, Saksamaa, Soome, Suurbritannia, Sveits, Taani, Ungari, uus-Meremaa
Micofenolato de mofetilo Hispaania
Mycophenolate mofetil Belgia, Saksamaa, Suurbritannia
Viited   Süsteravim   Viited : Mycophenolate mofetil  
tüüp avaldamine
1981 ajaleht Certain E, Beteta F, Goudou-Sinha C, Darbord JC, Prognon P, Jacquot C.
Stability of i.v. mycophenolate mofetil in 5% dextrose injection in polyvinyl chloride infusion bags.
Am J Health-Syst Pharm 2002 ; 59: 2434-2439.
1982 ajaleht Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2108 ajaleht Trusley C, Kupiec TC, Trissel LA.
Compatibility of micafungin injection with other drugs during simulated Y-site co-administration.
Int J Pharm Compound 2006 ; 10: 230-232.
2192 ajaleht Cochran BG, Sowinski KM, Fausel C, Overholser BR.
Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs.
Am J Health-Syst Pharm 2007 ; 64, 13: 1410-1414.
2247 ajaleht Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
3728 ajaleht Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3828 plakat Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 plakat So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
4055 ajaleht Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4299 ajaleht Ezquer-Garin C, Ferriols-Lisart R, Alos-Alminana M.
Stability of mycophenolate mofetil in polypropylene 5% dextrose infusion bags and chemical compatibility associated with the use of the EQUASHIELD® closed-system transfer device.
Biomed Chromatogr 2019 ; 33, 7: e4529.
4528 ajaleht Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4698 ajaleht Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022

  Mentions Légales